HRPK20050421B3 - Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin - Google Patents
Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skinInfo
- Publication number
- HRPK20050421B3 HRPK20050421B3 HR20050421A HRP20050421A HRPK20050421B3 HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3 HR 20050421 A HR20050421 A HR 20050421A HR P20050421 A HRP20050421 A HR P20050421A HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3
- Authority
- HR
- Croatia
- Prior art keywords
- application
- amphipats
- aggregate
- vivo
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41784702P | 2002-10-11 | 2002-10-11 | |
| US10/357,617 US7473432B2 (en) | 2002-10-11 | 2003-02-04 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| US10/357,618 US20040105881A1 (en) | 2002-10-11 | 2003-02-04 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| PCT/EP2003/011202 WO2004032900A1 (en) | 2002-10-11 | 2003-10-09 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20050421A2 HRP20050421A2 (en) | 2005-12-31 |
| HRPK20050421B3 true HRPK20050421B3 (en) | 2007-06-30 |
Family
ID=32995875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050421A HRPK20050421B3 (en) | 2002-10-11 | 2005-05-11 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
Country Status (22)
| Country | Link |
|---|---|
| EP (5) | EP1815847A3 (xx) |
| JP (3) | JP2006505619A (xx) |
| KR (1) | KR20050055723A (xx) |
| CN (1) | CN1703199B (xx) |
| AT (1) | ATE381316T1 (xx) |
| AU (1) | AU2003273977B2 (xx) |
| BR (1) | BR0315148A (xx) |
| CA (1) | CA2498938A1 (xx) |
| DE (1) | DE60318227T2 (xx) |
| DK (1) | DK1551370T3 (xx) |
| EA (1) | EA010407B1 (xx) |
| ES (1) | ES2298566T3 (xx) |
| HK (1) | HK1079113A1 (xx) |
| HR (1) | HRPK20050421B3 (xx) |
| IS (1) | IS7776A (xx) |
| MX (1) | MXPA05003744A (xx) |
| NO (1) | NO20052281L (xx) |
| NZ (1) | NZ538571A (xx) |
| PL (1) | PL377202A1 (xx) |
| PT (1) | PT1551370E (xx) |
| SI (1) | SI1551370T1 (xx) |
| WO (1) | WO2004032900A1 (xx) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
| ATE216223T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Transnasaler transport bzw. impfung mit hochadaptierbaren trägern |
| KR20070086045A (ko) * | 2004-11-12 | 2007-08-27 | 이데아 아게 | 피부 상태 치료에서의 확대된 표면 집합체 |
| CA2698293A1 (en) * | 2007-09-13 | 2009-03-26 | Thomas Subkowski | Use of hydrophobin polypeptides as penetration intensifiers |
| PL214538B1 (pl) | 2009-05-28 | 2013-08-30 | P P F Hasco Lek Spolka Akcyjna | Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen |
| EA029132B1 (ru) * | 2009-06-03 | 2018-02-28 | Секвессам Текнолоджи Холдингс Лимитед | Составы в виде везикул для лечения боли, связанной с остеоартритом |
| NZ598906A (en) * | 2009-08-21 | 2014-08-29 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| DE112012001386T5 (de) * | 2011-03-21 | 2013-12-19 | Gregor Cevc | Optimierte Präparate von sehr anpassungsfähigen Aggregaten |
| WO2012126965A1 (en) * | 2011-03-21 | 2012-09-27 | Gregor Cevc | Drug-free compositions and methods for diminishing peripheral inflammation and pain |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| CA2889664C (en) * | 2012-10-26 | 2020-12-29 | Oxford Nanopore Technologies Limited | Droplet interfaces |
| RU2524649C1 (ru) * | 2013-07-24 | 2014-07-27 | Станислав Анатольевич Кедик | Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма |
| CN114949237A (zh) * | 2013-07-31 | 2022-08-30 | 斯昆申技术控股有限责任公司 | 囊泡 |
| US10175256B2 (en) * | 2013-09-26 | 2019-01-08 | National University Of Singapore | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
| CN105658782B (zh) * | 2013-10-25 | 2018-08-07 | 凸版印刷株式会社 | 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法 |
| EP3954361A1 (en) | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
| EP3606557A4 (en) * | 2017-04-03 | 2020-12-16 | The Regents of The University of California | MOLDABLE NANOSCALE CARRIERS (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN BARRIER, MUCCOUS AND SKIN |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR102149190B1 (ko) | 2018-04-09 | 2020-08-28 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
| WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
| AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR102209397B1 (ko) | 2020-07-21 | 2021-01-29 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
| JP3765579B2 (ja) * | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| DE4447287C1 (de) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| DE4447277A1 (de) * | 1994-12-30 | 1996-07-04 | Hoechst Ag | Stabilisierte, phosphormodifizierte Epoxidharze und ihre Verwendung |
| DE69825495T2 (de) * | 1998-12-23 | 2005-07-28 | Idea Ag | Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo |
| ATE216223T1 (de) * | 1999-01-27 | 2002-05-15 | Idea Ag | Transnasaler transport bzw. impfung mit hochadaptierbaren trägern |
-
2003
- 2003-10-09 WO PCT/EP2003/011202 patent/WO2004032900A1/en active Application Filing
- 2003-10-09 EP EP06023468A patent/EP1815847A3/en not_active Withdrawn
- 2003-10-09 PT PT03757944T patent/PT1551370E/pt unknown
- 2003-10-09 CA CA002498938A patent/CA2498938A1/en not_active Abandoned
- 2003-10-09 EP EP06023467A patent/EP1829528A3/en not_active Withdrawn
- 2003-10-09 EP EP06023466A patent/EP1829527A3/en not_active Withdrawn
- 2003-10-09 MX MXPA05003744A patent/MXPA05003744A/es active IP Right Grant
- 2003-10-09 EA EA200500632A patent/EA010407B1/ru not_active IP Right Cessation
- 2003-10-09 EP EP03757944A patent/EP1551370B1/en not_active Expired - Lifetime
- 2003-10-09 AT AT03757944T patent/ATE381316T1/de active
- 2003-10-09 KR KR1020057004979A patent/KR20050055723A/ko not_active Application Discontinuation
- 2003-10-09 JP JP2005500984A patent/JP2006505619A/ja active Pending
- 2003-10-09 ES ES03757944T patent/ES2298566T3/es not_active Expired - Lifetime
- 2003-10-09 PL PL377202A patent/PL377202A1/pl not_active Application Discontinuation
- 2003-10-09 BR BR0315148-4A patent/BR0315148A/pt not_active IP Right Cessation
- 2003-10-09 AU AU2003273977A patent/AU2003273977B2/en not_active Ceased
- 2003-10-09 CN CN2003801013013A patent/CN1703199B/zh not_active Expired - Fee Related
- 2003-10-09 EP EP06023465A patent/EP1815846A3/en not_active Withdrawn
- 2003-10-09 DE DE60318227T patent/DE60318227T2/de not_active Expired - Lifetime
- 2003-10-09 SI SI200331142T patent/SI1551370T1/sl unknown
- 2003-10-09 DK DK03757944T patent/DK1551370T3/da active
- 2003-10-09 NZ NZ538571A patent/NZ538571A/en not_active IP Right Cessation
-
2005
- 2005-02-15 JP JP2005037992A patent/JP4555111B2/ja not_active Expired - Fee Related
- 2005-03-30 IS IS7776A patent/IS7776A/is unknown
- 2005-05-10 NO NO20052281A patent/NO20052281L/no not_active Application Discontinuation
- 2005-05-11 HR HR20050421A patent/HRPK20050421B3/xx not_active IP Right Cessation
- 2005-12-09 HK HK05111310A patent/HK1079113A1/xx not_active IP Right Cessation
-
2008
- 2008-11-04 JP JP2008283199A patent/JP2009108070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRPK20050421B3 (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| UA83350C2 (ru) | Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу | |
| ES2241145T3 (es) | Dispositivo y metodo para el tratamiento de heridas. | |
| WO2005000161A3 (en) | Methods and devices for occluding body lumens and/or for delivering therapeutic agents | |
| ATE89717T1 (de) | Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff. | |
| WO2004019921A3 (en) | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases | |
| RU2005138915A (ru) | Сульфонамид замещенные имидазохинолины | |
| CA2330207A1 (en) | Microneedle devices and methods of manufacture and use thereof | |
| JP2004536045A5 (xx) | ||
| WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
| WO2000072823A8 (en) | Preparations for the application of anti-inflammatory agents | |
| ITTO930661A0 (it) | Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico. | |
| Labi et al. | The Grief Brigade. | |
| WO2004096172A3 (fr) | Vecteur pour administration par voie orale | |
| HK1027762A1 (en) | Use of hydrophilic solvent extract of mushroom in the preparation of drug or food for preventing andtreating kidney disease. | |
| WO2002000170A3 (en) | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer | |
| ES2135476T3 (es) | Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson. | |
| WO2001017582A3 (en) | Bifurcated shunt drug delivery system and methods of use | |
| Martin et al. | Overview of N-(phosphonacetyl)-L-aspartate+ fluorouracil in clinical trials | |
| Booth | Managing partnerships seen as future technology | |
| Boulton | Combination drug treatment benefits patients with HIV. | |
| SE9902317D0 (sv) | Bår | |
| RU2002127274A (ru) | Применение препарата ветом-7048 впервые в качестве лекарственного препарата при лечении атрофии мозга, гидроцефалии мозга | |
| RU2004136836A (ru) | Способ профилактики послеродовых заболеваний у коров | |
| RU97105491A (ru) | Способ приживления кожных тканей при пластических операциях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AKOB | Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent) | ||
| PKB1 | Consensual patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110722 Year of fee payment: 9 |
|
| PBKO | Lapse due to non-payment of renewal fee for consensual patent |
Effective date: 20121010 |